S&P Futures
5,909.25 +3.25 (+0.06%) Dow Futures
43,549.00 +31.00 (+0.07%) Nasdaq Futures
20,489.50 +6.00 (+0.03%) Russell 2000 Futures
2,294.80 +3.60 (+0.16%) Crude Oil
69.59 +0.37 (+0.53%) Gold
2,746.60 +16.60 (+0.61%)
Cytokinetics, Incorporated (CYTK)
After hours:
| Previous Close | 54.53 |
| Open | 54.45 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 54.07 - 55.15 |
| 52 Week Range | 30.37 - 110.25 |
| Volume | |
| Avg. Volume | 1,232,531 |
| Market Cap | 6.468B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.36 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 82.41 |
Insider MonkeyIs Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Cytokinetics Inc. (NASDAQ:CYTK) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk, making them some of the most volatile in the market. […]
GlobeNewswireCytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM Beyond The Heart” for Health Care Professionals SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cytokine
